AustriaAustria

Intercell Expands to Scotland

09.04.2004

Vienna - Austrian biotech company Intercell AG acquired a multi-purpose biologics manufacturing plant in Living-ston, Scotland. Intercell will use the manufacturing capacity for its late-stage Japanese encephalitis vaccine and for its vaccine pipeline resulting from its bacterial antigen identification research and development programmes. Alexander von Gabain, Inter-cell's CEO: “Scotland's vibrant science community and excellent reputation for the quality of its research and production were a big incentives for Intercell to expand operations to Edinburgh.”
The 30,000 square foot, state-of-the-art GMP facility was formerly owned by Excell Biotech, and has only recently become fully operational. The facility is designed according to the most up-to-date international standards for biologics product manufacturing. Through the acquisition, Intercell will also access the skills of a team of highly experienced staff with a broad expertise in process development, manufacturing and quality management of viral and recombinant protein products.
“This strategically very important acquisition will allow Intercell to fully control the clinical and future commercial manufacturing of our Japanese encephalitis vaccine, which is planned to enter phase III clinical trials in early 2005. Furthermore we will have the capabilities to develop and produce in-house any future recombinant bacterial vaccines resulting from our innovative Antigen Identification Programme“, commented COO Gerd Zettlmeissl.
Intercell has been supported by Scottish Development International and Scottish Enterprise Edinburgh and Lothian.

AustriaAustria

03.11.2010

Austrian vaccine developer Intercell AG (Vienna) has a new Chief Business Officer. At the beginning of October, Staph Leavenworth Bakali quit Intercell’s supervisory board and joined its management board with key responsibilities...

AustriaAustria

03.11.2010

Vienna – Austrian vaccine specialist Intercell AG has landed a new partner for its therapeutic vaccine IC41 against chronic infections with the hepatitis C virus (HCV) after Novartis quit a a 270m partnership with the firm this...

AustriaAustria

16.09.2010

Bremen/Vienna/Galway – A novel protein glue that helps colonies of the barnacle Dosima fascicularis to float on the surface of the water and stick to vessels could inspire the next revolution in medicine and material sciences....

AustriaAustria

18.08.2010

Vienna – Austrian vaccine specialist Intercell AG increased R&D spending by 24% in the second quarter of 2010 to EUR16.9m due to expenditures linked to clinical Phase III testing of its traveller's diarrhoea vaccine. That...

AustriaAustria

19.07.2010

An estimated 20,000 participants from over 185 countries are taking part in the 18th International AIDS Conference that began in Vienna on Sunday. The head of the International AIDS Society, and conference chairman, Julio...

AustriaAustria

14.07.2010

Vienna – Swissmedic has approved IXIARO®, a vaccine against Japanese encephalitis from Intercell AG that is distributed and marketed by Novartis AG. The decision by the Swiss authorities is another important milestone for the...

AustriaAustria

10.07.2010

Vienna – Austria’s Intercell AG has closed the acquisition of Cytos’ platform technology for monoclonal antibody discovery, which is based on expression cloning of monoclonal antibodies from human B-cells. As per agreed terms,...

AustriaAustria

12.05.2010

Vienna – Invoking the EU’s safeguard clause, the Austrian parliament has unanimously instructed its Ministry of Health to establish a specific legal measure to prohibit the cultivation of the biotech potato Amflora in the...

AustriaAustria

07.05.2010

Vienna – Austrian Intercell AG expands its current vaccine business to anti-infective monoclonal antibodies. In a EUR 15 million deal Intercell has bought Cytos' antibody discovery platform technology, the firm announced on 6th...

Displaying results 21 to 30 out of 116

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/2/article/intercell-expands-to-scotland.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.13 CHF4.68%
  • CO.DON3.15 EUR4.30%
  • BB BIOTECH146.25 EUR2.17%

FLOP

  • WILEX2.35 EUR-5.24%
  • SANTHERA89.15 CHF-3.10%
  • EVOTEC2.93 EUR-2.33%

TOP

  • SANTHERA89.15 CHF31.2%
  • CO.DON3.15 EUR26.0%
  • PAION3.01 EUR24.4%

FLOP

  • ADDEX3.13 CHF-22.3%
  • EVOTEC2.93 EUR-21.2%
  • MEDIGENE3.95 EUR-15.1%

TOP

  • SANTHERA89.15 CHF2117.7%
  • CO.DON3.15 EUR250.0%
  • PAION3.01 EUR189.4%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.67 EUR-40.6%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014


Current issue

All issues

Product of the week

Products